Trial · NCT00167102

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102, Not applicable, Completed, University of Minnesota; results first posted 2013-04-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Alefacept in Patients With Severe Scalp Alopecia Areata. Trials, record NCT00167102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00167102

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Alefacept in Patients With Severe Scalp Alopecia Areata
NCT number: NCT00167102
Status: Completed
Phases: Not applicable
Enrollment: 45 participants, actual
Lead sponsor: University of Minnesota
Conditions: Alopecia Areata
Interventions: Alefacept
First posted: 2005-09-14
Last updated: 2019-05-22
Results first posted: 2013-04-09
Limitations and caveats: This study was limited by the number of patients randomized to receive treatment.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values	24 weeks	Assess the therapeutic efficacy of a 12-week regimen of weekly IM administration of alefacept followed by a 12 week observation period in subjects with chronic severe scalp alopecia
Primary	Number of Adverse Events	24 weeks	Number of any adverse event reported throughout the study, regardless of relation to study drug

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values	24 weeks		percentage of participants	NUMBER
PRIMARY	Number of Adverse Events	24 weeks		adverse events	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values	Alefacept	8.7	percentage of participants
The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values	Placebo	13.6	percentage of participants
Number of Adverse Events	Alefacept	20	adverse events
Number of Adverse Events	Placebo	20	adverse events

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Alefacept	23
Overall Study	STARTED	Placebo	22
Overall Study	COMPLETED	Alefacept	23
Overall Study	COMPLETED	Placebo	22
Overall Study	NOT COMPLETED	Alefacept	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Congestion	Respiratory, thoracic and mediastinal disorders	Alefacept	8	23
other	Congestion	Respiratory, thoracic and mediastinal disorders	Placebo	2	22
other	Infection	Infections and infestations	Alefacept	4	23
other	Infection	Infections and infestations	Placebo	3	22
other	Cold	Infections and infestations	Alefacept	4	23
other	Cold	Infections and infestations	Placebo	2	22
other	Headaches	General disorders	Alefacept	4	23
other	Headaches	General disorders	Placebo	3	22
other	Nausea	Gastrointestinal disorders	Alefacept	2	23
other	Nausea	Gastrointestinal disorders	Placebo	1	22

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Alefacept
Total, all-cause mortality	Placebo
Total, other adverse events	Alefacept	20	23
Total, other adverse events	Placebo	9	22
Total, serious adverse events	Alefacept	1	23
Total, serious adverse events	Placebo	2	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Alefacept vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00167102

GET https://conductscience.org/api/trials/v1/NCT00167102/registered

API reference For AI assistants